Benefits have shifted from a line item to a balance-sheet risk. Medical trend is sticky, pharmacy inflation is accelerating, chronic disease is showing up earlier in life, and workplace expectations are rewriting the talent contract. The organizations that hold cost and risk in check will run benefits like a portfolio: set a strategy and adjust as new data arrives.
Here are the four forces that will influence decisions in 2026 with the potential to change outcomes rather than merely adjust prices.
The Health of the Nation
Cancer patterns are moving into working-age cohorts. Pediatric and adolescent-onset chronic conditions are rising and persisting into adulthood. Women’s health needs are only partially served by current benefits. Oral health remains an underused lever that affects total medical spend. Environmental exposures, including wildfire smoke events that degrade air quality far from the source, now create intermittent health and operational risk. Eldercare has quietly overtaken childcare as the more common caregiving burden and is driving turnover when support is thin.
The through line is a preventable cost. Earlier detection, simplified navigation, and smarter plan design change the cost curve when executed with precision.
What to do in 2026
Align plan coverage with current guidelines for cancer and cardiovascular screenings. Use proactive outreach and pre-scheduled appointments to remove friction. Tie vendor performance guarantees to screening completion and time to diagnosis.
Treat women’s health as a continuum by moving beyond a narrow focus on fertility and menopause. Ensure access and navigation for conditions that disproportionately affect women, including autoimmune disease, depression, migraine, and metabolic disorders. Employer adoption of menopause support has been growing rapidly: Mercer found that the share of large organizations (500 or more employees) offering or planning to offer a specialized menopause benefit jumped from 4% in 2022 to 15% in 2023, as workforce demand and clinical evidence around midlife women’s health have continued to build.
Build eldercare into core benefits. Offer backup care, care navigation, legal and financial guidance, and grief counseling. Make managers aware of available tools. Retention depends on it.
Use dental benefits to reduce medical spend. Pay first-dollar for preventive visits. Incorporate periodontal treatment pathways for members with diabetes, cardiovascular disease, or pregnancy. Poor oral health drives complications that are far more expensive than a cleaning.
Add environmental readiness to the health plan. Pre-negotiate HVAC filter supply, validate indoor air quality monitoring, and align policies to state requirements for smoke events. Stand up a rapid-response communication plan for air quality incidents.
Pharmacy Trends
Pharmacy is the fastest-moving piece of the portfolio. Specialty therapies dominate spend, and GLP-1 medications for obesity and diabetes are now a structural factor in both short-term budgets and long-term risk. Employers cannot set drug prices, but they can determine how their plan buys, how coverage is sequenced, and which clinical and financial protections apply.
Two principles matter: move from unit-cost obsession to total-value control, and treat the PBM relationship as a contract to be actively governed every quarter, not filed until renewal.
Key realities to anchor planning
The pharmacy trend is forecast to remain a significant cost pressure in 2026. According to the Business Group on Health’s annual employer survey, employers anticipate continued double-digit increases in benefit costs in some regions, driven by specialty drug utilization, GLP-1 growth, and rising inflation across the pharmacy supply chain.
Three therapeutic areas dominate specialty spend: oncology, immunology, and metabolic disease. Biosimilars are arriving, but payer design determines whether they are used. Roughly three-quarters of the approximately 7,000 drugs in development as of mid-2024 were specialty therapies, signaling more high-cost launches ahead.
What to do in 2026
Specify definitions in writing. In many PBM contracts, the definition of “specialty” drives pricing, rebates, and utilization rules. Define it precisely and fix it for the contract term to avoid silent reclassification.
Enforce biosimilar-first. Set a biosimilar-first policy with clear medical exception rules and member communications. Monitor uptake monthly and tie service fees to adoption.
Right-size GLP-1 coverage to risk. Separate obesity and diabetes coverage policies. Use step therapy anchored in evidence, structured adherence support, realistic discontinuation criteria, and outcomes measurement. The goal is clinical impact per dollar, not blanket denial or open access.
Stress-test stop-loss. High-cost oncology and cell and gene therapies create volatility. Review stop-loss terms for new-therapy handling, accumulation periods, and disclosure obligations. Model tail risk and coverage gaps before renewal.
Pursue outcomes-based value where measurement is credible. Oncology and GLP-1 therapies lend themselves to outcomes-based arrangements. Confirm how performance is measured, how rebates reconcile, and how member access is protected during disputes.
Healthcare Economics
Prices are rising while rules are changing. ACA marketplace premiums have seen their steepest increases in years as enhanced premium tax credits expired on December 31, 2025. According to KFF analysis, this expiration is estimated to increase premium payments for marketplace enrollees by an average of 114%, and insurers raised premiums roughly 20% on average for plan year 2026 in response to the expected adverse selection as healthier enrollees drop coverage.
At the same time, transparency regulations are forcing carriers and providers to expose contracted rates. That data gives employers a clearer view of price variance by facility, specialty, and geography.
Funding model choice and network configuration now have measurable cause and effect. Employers that combine the right funding structure with transparent data and predictive analytics can move spend, not just explain it.
What to do in 2026
Match funding to volatility. Fully insured plans trade predictability for higher long-run cost. Self-funding improves control but adds variance. Partial self-funding or level funding can bridge the gap. Pick the model that fits the organization’s risk tolerance and cash flow, then revisit annually.
Use transparency to rebalance networks. Identify high-variance services such as imaging, ambulatory surgery, and infusions. Shift steerage, renegotiate centers of excellence, and deploy surgical bundles where quality and price are defensible. Hold vendors to measurable redirection targets.
Modernize risk management. Deploy predictive AI to flag high-cost trajectories early, focusing on oncology, musculoskeletal, and cardiometabolic risk. Build rapid outreach and navigation into care management, so alerts translate into avoided claims, not dashboards.
Align incentives across vendors. Carve-outs, navigation, and disease management often operate in silos. Consolidate performance metrics around total cost of care and time to clinically appropriate care. Pay for delivered outcomes, not completed phone calls.
Workforce and Technology
Change fatigue is persistent, so the next generation is skeptical of middle management as a career path. Flexibility has emerged as the clearest stabilizer. Hybrid roles correlate with higher engagement and lower turnover, and return-to-office mandates increase attrition when they ignore job structure and location realities. A randomized controlled trial published in Nature in June 2024, involving 1,612 employees at Trip.com, found that hybrid work reduced attrition by 33% overall compared with the fully in-office group, with no measurable difference in performance reviews or promotion rates.
Another big issue is the fact that AI adoption is outpacing governance in many organizations. Gartner predicts that 40% of enterprise applications will be integrated with task-specific AI agents by the end of 2026, up from less than 5% in 2025. It is a shift that requires governance infrastructure to be in place before, not after, deployment. Agentic AI raises the stakes even further as they unfortunately plan and act with minimal supervision. Stop treating agents like chat tools because they will produce operational sprawl. Instead, approach them as services with service-level agreements, not employees with job descriptions.
What to do in 2026
Make flexibility a design principle by classifying roles by task type. Define on-site, hybrid, and remote criteria by work outcomes. Measure engagement, quality, and attrition side by side to validate the model.
Build a pay transparency operating system. Standardize job architecture, create defensible pay bands, and publish ranges wherever legally permitted. Educate managers so conversations about pay are accurate and consistent.
Support eldercare with the same rigor given to childcare. Offer care navigation, vetted local resources, and backup days. Track usage and retention among caregivers to confirm ROI.
Operationalize AI governance. Stand up a cross-functional council with representation from HR, IT, security, compliance, and legal. Approve use cases, define model and data controls, and establish incident response. Treat AI agents as services with SLAs that specify accuracy thresholds, escalation paths, and audit logging.
Close the training gap. Map high-frequency tasks to AI tools. Provide short, task-based training and certify usage. Most AI compliance failures are unintentional. Training reduces risk while unlocking productivity.
How to Integrate the Levers
The playbook works only if it is integrated. Pharmacy controls will not land without strong clinical programs. Transparency data will not change spending without steerage and member navigation. AI oversight will not matter if the underlying data is incomplete. Build a unified dashboard that links leading indicators to accountable owners, and review it monthly at the executive level.
Metrics that matter in this cycle
Preventive care completion rates by cohort, not just overall. Time to first specialty visit after a positive screening. Biosimilar adoption rate and GLP-1 persistence by indication. Unit price variance for the top 20 shoppable services by market. Caregiver benefit utilization and correlated retention. AI incident rate, model accuracy against SLA, and user certification coverage.
Procurement, finance, HR, and clinical partners should see the same measures and the same targets. That ensures trade-offs are explicit. A pharmacy carve-out that raises short-term disruption but pays for itself in year one is a different decision than a narrow network that lowers unit cost but increases travel time and no-shows. Put those tensions on the table and decide on purpose.
Conclusion
The fundamental tension in 2026 lies in the decision of where to absorb costs. Shifting expenses to employees is structurally straightforward and may be unavoidable for some plans. But without parallel investment in prevention, navigation, and contract discipline, cost-shifting delays rather than resolves the underlying drivers. Claims do not disappear when deductibles rise; they migrate to later stages of disease, higher acuity, and larger stop-loss events.
The same dynamic applies to technology adoption in complex, regulated environments: moving fast without governance infrastructure tends to concentrate risk rather than distribute it. Organizations that treat AI deployment as an operational discipline rather than a productivity shortcut will be better positioned to avoid the compliance and data-quality failures already surfacing among early adopters.
Benefits strategy in 2026 will be defined less by which programs employers offer and more by how tightly those programs are governed, measured, and adjusted. The employers with the clearest performance data and the shortest feedback loops will have the most options when conditions shift.
